Patient-derived xenograft (PDX) tumors increase growt

Oncotarget

7, 7993-8005

DOI: 10.18632/oncotarget.6919

Citation Report

#	Article	IF	Citations
1	Heralding a new paradigm in 3D tumor modeling. Biomaterials, 2016, 108, 197-213.	5.7	127
2	Patient-derived xenografts as in vivo models for research in urological malignancies. Nature Reviews Urology, 2017, 14, 267-283.	1.9	65
3	Barriers to generating PDX models of HPVâ€related head and neck cancer. Laryngoscope, 2017, 127, 2777-2783.	1.1	33
4	A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug. Scientific Reports, 2017, 7, 11410.	1.6	39
5	Current status and perspectives of patient-derived xenograft models in cancer research. Journal of Hematology and Oncology, 2017, 10, 106.	6.9	214
6	5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2017, 23, 2516-2527.	3.2	39
7	Therapeutic Inhibition of the MDM2â€“p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clinical Cancer Research, 2017, 23, 1036-1048.	3.2	27
8	Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. Clinical Cancer Research, 2018, 24, 2935-2943.	3.2	25
9	A patient derived xenograft model of cervical cancer and cervical dysplasia. PLoS ONE, 2018, 13, e0206539.	1.1	20
10	UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line. Oral Oncology, 2018, 87, 21-28.	0.8	23
11	Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. Oncology Reports, 2018, 40, 635-646.	1.2	26
12	A comparison of next-generation sequencing analysis methods for cancer xenograft samples. Journal of Genetics and Genomics, 2018, 45, 345-350.	1.7	5
13	Establishment and characterization of patient-derived xenograft and its cell line of primary leiomyosarcoma of bone. In Vitro Cellular and Developmental Biology - Animal, 2018, 54, 458-467.	0.7	5
14	Xenograft and organoid model systems in cancerÂresearch. EMBO Journal, 2019, 38, e101654.	3.5	257
15	Target Identification and Validation in Drug Discovery. Methods in Molecular Biology, 2019, , .	0.4	1
16	In Vivo Pharmacology Models for Cancer Target Research. Methods in Molecular Biology, 2019, 1953, 183-211.	0.4	8
17	Patientâ€derived xenografts of a case of ameloblastic fibrodentinoma. Oral Diseases, 2019, 25, 1229-1233.	1.5	3
18	Serial patient-derived orthotopic xenografting of adenoid cystic carcinomas recapitulates stable expression of phenotypic alterations and innervation. EBioMedicine, 2019, 41, 175-184.	2.7	11

#	Article	IF	Citations
19	Capturing colorectal cancer interâ€tumor heterogeneity in patientâ€derived xenograft (PDX) models. International Journal of Cancer, 2019, 144, 366-371.	2.3	32
20	Multiregion Genomic Analysis of Serially Transplanted Patient-derived Xenograft Tumors. Cancer Genomics and Proteomics, 2019, 16, 21-27.	1.0	13
21	Keeping Score: Semiquantitative and Quantitative Scoring Approaches to Genetically Engineered and Xenograft Mouse Models of Cancer. Veterinary Pathology, 2019, 56, 24-32.	0.8	4
22	The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance. International Journal of Cancer, 2020, 146, 2078-2088.	2.3	70
23	First insights for targeted therapies in odontogenic myxoma. Clinical Oral Investigations, 2020, 24, 2451-2458.	1.4	12
24	Modeling neoplastic disease with spheroids and organoids. Journal of Hematology and Oncology, 2020, 13, 97.	6.9	122
25	Report of the use of patientâ€derived xenograft models in the development of anticancer drugs in Japan. Cancer Science, 2020, 111, 3386-3394.	1.7	10
26	Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer. Cancers, 2020, 12, 3743.	1.7	19
27	Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor. Cancer Communications, 2020, 40, 285-300.	3.7	24
28	Mouse Tumor-Bearing Models as Preclinical Study Platforms for Oral Squamous Cell Carcinoma. Frontiers in Oncology, 2020, 10, 212.	1.3	49
29	Novel Breast Cancer Brain Metastasis Patient-Derived Orthotopic Xenograft Model for Preclinical Studies. Cancers, 2020, 12, 444.	1.7	25
30	Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma. Cancers, 2020, 12, 871.	1.7	9
31	Bioengineered tissue models for the development of dynamic immuno-associated tumor models and high-throughput immunotherapy cytotoxicity assays. Drug Discovery Today, 2021, 26, 455-473.	3.2	2
32	Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors. International Journal of Cancer, 2021, 149, 277-286.	2.3	7
33	Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma. BMC Cancer, 2021, 21, 265.	1.1	2
34	Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188523.	3.3	25
36	Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. Frontiers in Oncology, 2021, 11, 704042.	1.3	5
37	Impact of photobiomodulation in a patientâ€derived xenograft model of oral squamous cell carcinoma. Oral Diseases, 2023, 29, 547-556.	1.5	7

#	Article	IF	Citations
38	Drug discovery oncology in a mouse: concepts, models and limitations. Future Science OA, 2021, 7, FSO737.	0.9	6
39	Establishment of <scp>PDX</scp>â€derived salivary adenoid cystic carcinoma cell lines using organoid culture method. International Journal of Cancer, 2021, 148, 193-202.	2.3	16
40	Bridging the divide: preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors. Oncotarget, 2017, 8, 113269-113281.	0.8	44
41	Increasing aggressiveness of patient-derived xenograft models of cervix carcinoma during serial transplantation. Oncotarget, 2018, 9, 21036-21051.	0.8	12
42	EPR effect and development of new strategy for nanoparticle delivery via remodeling tumor microenvironment based on tumor vasculature targeting. Drug Delivery System, 2018, 33, 98-104.	0.0	1
43	The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells. Cell Death and Disease, 2021, 12, 988.	2.7	27
47	Salivary gland cancer in the setting of tumor microenvironment: Translational routes for therapy. Critical Reviews in Oncology/Hematology, 2022, 171, 103605.	2.0	4
48	Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research. Frontiers in Oncology, 2022, 12, 837233.	1.3	2
49	Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research. Cancers, 2021, 13, 6288.	1.7	15
51	Patient-derived xenograft (PDX) models, applications and challenges in cancer research. Journal of Translational Medicine, 2022, 20, 206.	1.8	78
52	Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models. EMBO Molecular Medicine, 2022, 14, .	3.3	6
53	Role of Patient-Derived Models of Cancer in Translational Oncology. Cancers, 2023, 15, 139.	1.7	11
54	Establishment of experimental salivary gland cancer models using organoid culture and patient-derived xenografting. Cellular Oncology (Dordrecht), 2023, 46, 409-421.	2.1	2
55	Zebrafish Cancer Avatars: A Translational Platform for Analyzing Tumor Heterogeneity and Predicting Patient Outcomes. International Journal of Molecular Sciences, 2023, 24, 2288.	1.8	5
56	Early Cell Cultures from Prostate Cancer Tissue Express Tissue Specific Epithelial and Cancer Markers. International Journal of Molecular Sciences, 2023, 24, 2830.	1.8	0
57	Application status and future prospects of the PDX model in lung cancer. Frontiers in Oncology, 0, 13, .	1.3	3
60	Patient-derived tumor models: a suitable tool for preclinical studies on esophageal cancer. Cancer Gene Therapy, 0, , .	2.2	0